伐尼克兰在水烟烟草吸烟者中实现戒断的疗效——一项随机对照试验的研究方案
本研究为在巴基斯坦旁遮普省四个地区开展的两臂、双盲、安慰剂对照随机试验,计划纳入510名每日使用水烟至少6个月且愿意戒烟的成人,比较伐尼克兰联合行为支持与安慰剂联合行为支持的效果,主要结局为生化验证的持续戒断至少6个月(第25周)。
要点
- 伐尼克兰联合行为支持对比安慰剂联合行为支持用于水烟戒断。
- 主要结局为第25周经一氧化碳<10 ppm验证的持续戒断至少6个月。
- 研究方案指出该疗效试验后续还需开展实效性试验以作最终评价。
核心结论
- 该研究旨在评估伐尼克兰联合行为支持对水烟烟草吸烟者戒断的疗效,通过生化验证的持续戒断进行测量。
- 研究方案指出这是一项疗效试验,后续还需开展实效性试验以对该干预措施进行最终评价。
研究设计与样本
- 两臂、双盲、安慰剂对照随机试验,在巴基斯坦旁遮普省四个地区开展。
- 研究对象为每日使用水烟至少6个月(可合并卷烟、比迪烟或其他形式烟草使用)且愿意戒烟的成人。
- 计划将510名参与者个体随机分配至两个试验组。
主要发现
- 干预组接受伐尼克兰联合行为支持,对照组接受安慰剂联合行为支持。
- 主要结局为持续戒断至少6个月(第25周),经一氧化碳水平<10 ppm生化验证。
- 次要结局包括第5、12和25周经生化验证的7天时点戒断以及不同评估点之间的任何失戒和复吸。
- 三级结局包括使用情绪与躯体症状量表(MPSS)评估戒断症状、使用黎巴嫩水烟依赖量表(LWDS-11)评估吸烟依赖以及监测不良结局。
关键数值与推荐
- 主要结局持续戒断的生化验证标准为一氧化碳水平<10 ppm。
临床怎么用
- 原文未据此给出推荐。
局限性
- 研究方案指出这是一项疗效试验,后续还需开展实效性试验以对该干预措施进行最终评价。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Waterpipe tobacco smoking has increased among youth across the globe including in the US, and it continues as a common and traditional form of smoking tobacco in Pakistan. A range of behavioral and pharmacological therapies are available to support people in quitting cigarette smoking; however, little evidence exists for the efficacy of these therapies in achieving abstinence among waterpipe tobacco smokers. The objective of this study is to assess the efficacy of varenicline when added to behavioral support for waterpipe tobacco smoking cessation, by measuring biochemically validated continuous abstinence in waterpipe tobacco smokers. METHODS/DESIGN: This is a two-arm, double-blind, placebo-controlled randomized trial conducted in four districts in Punjab, Pakistan. Study participants include adults using a waterpipe (with or without concomitant cigarette, bidi or other forms of tobacco smoking) on a daily basis for at least 6 months and who are willing to quit. We will individually randomize 510 participants to one of the two arms of the trial. Participants in the intervention arm will receive varenicline and behavioral support and those in the control arm will receive placebo and behavioral support. The primary outcome will be continuous abstinence for at least 6 months (week 25) which is biochemically verified by a carbon monoxide level of <10 ppm. Secondary outcomes will include biochemically verified 7-day point abstinence at 5, 12 and 25 weeks and any lapses and relapses between the different assessment points. Tertiary outcomes will include assessment of withdrawal symptoms using the Mood and Physical Symptoms Scale (MPSS), smoking dependency using the Lebanon Waterpipe Dependency Scale (LWDS-11) and monitoring adverse outcomes. DISCUSSION: This is an efficacy trial and would require a subsequent effectiveness trial for a definitive evaluation of the intervention. TRIAL REGISTRATION: ISRCTN, ISRCTN94103375 . Registered on 1 December 2015.
引用
- Zahid R, Dogar O, Mansoor S, et al. The efficacy of varenicline in achieving abstinence among waterpipe tobacco smokers - study protocol for a randomized controlled trial. Trials. 2017. PMID: 28077163. doi:10.1186/s13063-016-1761-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。